HSA
CLVS

Hussman Strategic Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Hussman Strategic Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-51,500
Closed -$230K – 360
2021
Q3 		$230K Hold
51,500
– – 0.05% 287
2021
Q2 		$299K Hold
51,500
– – 0.06% 300
2021
Q1 		$362K Buy
+51,500
New +$345K 0.07% 286

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hussman Strategic Advisors's CLVS Position: Q4 2021 in Review

Hussman Strategic Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 51,500 shares — an estimated $230K sold.

Hussman Strategic Advisors first reported a position in CLVS in Q1 2021 and held it in 3 quarters. The position peaked at $362K in Q1 2021. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

  • Hussman Strategic Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 51,500 Clovis Oncology, Inc. shares in Q4 2021, an estimated $230K.
  • Hussman Strategic Advisors first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 3 quarters.
  • Hussman Strategic Advisors's Clovis Oncology, Inc. position peaked at $362K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Hussman Strategic Advisors's 13F filing for Q4 2021, filed 31 Jan 2022.